CancerDrs

Head and Neck Cancer clinical trials in Washington

25 actively recruiting head and neck cancer trials at 31 sites across Washington.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Washington:
  • Saint Francis Hospital — Federal Way, Washington
  • Tri-Cities Cancer Center — Kennewick, Washington
  • PeaceHealth Saint John Medical Center — Longview, Washington
  • Skagit Regional Health Cancer Care Center — Mount Vernon, Washington
  • University of Washington Medical Center - Montlake — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Washington:
  • Research Site — Olympia, Washington
  • Research Site — Seattle, Washington
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Washington:
  • Site 163 — Seattle, Washington
  • Site 6 — Spokane, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Washington:
  • Swedish Medical Center-First Hill — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
  • Mary Bridge Children's Hospital and Health Center — Tacoma, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Washington:
  • University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Washington:
  • Avenzo Therapeutics Recruiting Site — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Washington:
  • Wenatchee Hospitals and Clinics — Wenatchee, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04620187
Sites in Washington:
  • University of Washington Medical Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Washington:
  • Gynecology Oncology clinic at UW Medical Center - Montlake — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Washington:
  • Fred Hutchinson Cancer Research Center — Seattle, Washington
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Washington:
  • Northwest Medical Specialities. PLLC — Bonney Lake, Washington
  • Swedish Cancer Institute - Edmonds Campus — Edmonds, Washington
  • Swedish Cancer Institute Edmonds Campus — Edmonds, Washington
  • Northwest Medical Specialities.PLLC — Federal Way, Washington
  • Northwest Medical Specialities. PLLC — Gig Harbor, Washington
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, an…

Sponsor: AstraZeneca
NCT ID: NCT06147037
Sites in Washington:
  • Research Site — Seattle, Washington
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Sponsor: Solve Therapeutics
NCT ID: NCT06771219
Sites in Washington:
  • University of Washington / Fred Hutchinson Cancer Center — Seattle, Washington
  • Northwest Medical Specialties, PLLC — Tacoma, Washington
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Washington:
  • Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
  • PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
  • Highline Medical Center-Main Campus — Burien, Washington
  • Providence Regional Cancer System-Centralia — Centralia, Washington
  • Swedish Cancer Institute-Edmonds — Edmonds, Washington
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Washington:
  • Saint Michael Cancer Center — Silverdale, Washington
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Washington:
  • Massive Bio SYNERGY-AI site — Seattle, Washington
View on ClinicalTrials.gov →
Recruiting Industry

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use …

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT04981119
Sites in Washington:
  • Fred Hutchinson Cancer Center — Seattle, Washington
View on ClinicalTrials.gov →
Recruiting Academic/Other

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC ha…

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT05024929
Sites in Washington:
  • Seattle Children's Hospital — Seattle, Washington
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15